Drug profile · INN
belantamab mafodotin
BLENREP
belantamab mafodotin (BLENREP) is a tumor necrosis factor receptor superfamily member 17 binding agent.
Drug details — belantamab mafodotin
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.83
Quick answer
belantamab mafodotin (BLENREP) is a tumor necrosis factor receptor superfamily member 17 binding agent.
Key facts
Mechanism of action
Tumor necrosis factor receptor superfamily member 17 binding agent
Primary target: Tubulin
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
GSK’s Blenrep returns to the US market after FDA approves resubmission
The FDA has approved GSK’s Blenrep in combination with bortezomib and dexamethasone, clearing the drug’s return to the US market. The move ends a withdrawal that followed a failed confirmatory study and resets the catalyst timeline for investors and BD teams.
GSK Blenrep wins FDA approval in relapsed multiple myeloma
GSK’s Blenrep has returned to the U.S. market after the FDA approved it in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. The catalyst matters for BD teams and investors because it reverses a prior withdrawal and resets the drug’s U.S. label and commercial outlook.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is belantamab mafodotin?
belantamab mafodotin (BLENREP) is a tumor necrosis factor receptor superfamily member 17 binding agent.
What is the brand name for belantamab mafodotin?
BLENREP is a marketed brand name for belantamab mafodotin. Check FDA Drugs@FDA for the current US label holder and prescribing information.